Breaking News
July 16, 2018 - Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
July 16, 2018 - Restoring epigenetic balance reinstates memory in flies with Alzheimer’s disease symptoms
July 16, 2018 - Magnetized wire could be used to detect cancer in people | News Center
July 16, 2018 - Non-surgical management found to be feasible option for penetrating kidney trauma
July 16, 2018 - California clinic screens asylum seekers for honesty
July 16, 2018 - FDA Approves Xtandi (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
July 16, 2018 - Can nanotechnology help treat Alzheimer’s?
July 16, 2018 - Researchers identify protein essential for making stem cells | News Center
July 16, 2018 - Radiologist discusses causes, treatments of varicose veins
July 16, 2018 - Researchers develop nanostructured surface to accelerate wound healing after dental implants
July 16, 2018 - New non-invasive procedure to reposition kidney stones could benefit astronauts
July 16, 2018 - Attending Surgeon Influences Genetic Testing in Breast Cancer
July 16, 2018 - Medical doctors with addictions fear professional repercussions if they seek treatment
July 16, 2018 - 5 Questions: John Ioannidis calls for more rigorous nutrition research | News Center
July 16, 2018 - Researchers find definite increase in scooter-related injuries
July 16, 2018 - Researchers solve mystery of final blood group system
July 16, 2018 - Researchers develop near-infrared fluorophores-based PDT to cure cancer with less side effects
July 16, 2018 - Traumatic brain injury biomarker could help predict patient prognosis
July 16, 2018 - Researchers to investigate role of hormones in mosquito’s ability to use human blood for egg production
July 16, 2018 - AHA: Doctor Makes Lifesaving House Call in His Own Home
July 16, 2018 - Nearsightedness – Genetics Home Reference
July 16, 2018 - Study shows biomarker panel boosts lung cancer risk assessment for smokers
July 16, 2018 - Researchers find link between bereavement during pregnancy, child’s mental health | News Center
July 16, 2018 - Legalizing same-sex marriage has meaningful effects on health care access for sexual-minority men
July 16, 2018 - New York to allow medical marijuana as substitute to opioids
July 16, 2018 - Reducing tapeworm infection could improve academic performance, reduce poverty | News Center
July 16, 2018 - Researchers describe key role of enzyme in regulating immune response against Chagas disease parasite
July 16, 2018 - Johnson & Johnson Announces Publication in The Lancet Highlighting Robust Immune Response to Janssen’s Mosaic-based Preventive Vaccine Regimen for HIV
July 16, 2018 - Do Racial and Gender Disparities Exist in Newer Glaucoma Treatments?
July 16, 2018 - Antibodies may predict transplant rejection risk
July 16, 2018 - New center sets out to stop disease before it starts | News Center
July 16, 2018 - FDA warns consumers about criminals sending fake warning letters
July 16, 2018 - Residential segregation linked with racial disparities in firearm homicide fatalities
July 16, 2018 - UW-Madison researchers develop new method to track Parkinson’s damage in the heart
July 16, 2018 - New approach to cultivate hypoallergenic tomato and strawberry varieties
July 16, 2018 - Smoking associated with delayed shinbone healing
July 16, 2018 - Sheila Dolezal, ‘team player extraordinaire,’ wins 2018 Amy J. Blue Award | News Center
July 16, 2018 - Advanced Prostate Cancer Variant More Common Than Thought
July 16, 2018 - New ways to conquer sleep apnea compete for place in bedroom
July 16, 2018 - Renowned microbe hunter Stanley Falkow dies at 84 | News Center
July 15, 2018 - FDA Slaps Stronger Warnings on Potent Class of Antibiotics, Fluoroquinolones
July 15, 2018 - Don’t let depression keep you from exercising
July 15, 2018 - Student research symposium showcases curiosity and scholarship | News Center
July 15, 2018 - Heavy smokers have increased risk of heart rhythm disorder, shows study
July 15, 2018 - Parents who had severe trauma, stresses in childhood more likely to have kids with behavioral health problems
July 15, 2018 - At colloquium, a range of views on value of predictive algorithms | News Center
July 15, 2018 - Pittcon invites oral and poster presentations for 2019 Technical Program
July 15, 2018 - Virtual reality could offer psychotherapy for fear of heights, study shows
July 15, 2018 - Retooled vaccine raises hopes as a lower-cost treatment for Type 1 diabetes
July 15, 2018 - Kolon TissueGene To Start US Phase III Clinical Trial For Invossa
July 15, 2018 - Study finds prenatal marijuana use can affect infant size, behavior
July 15, 2018 - Howard Chang named HHMI investigator | News Center
July 15, 2018 - Study shows tailored mental health services improve wellbeing of emerging adults
July 15, 2018 - A bright future might help teens steer clear of violence
July 15, 2018 - Stanford Medicine magazine explores the art, science of listening and hearing | News Center
July 15, 2018 - New study tracks how the brain turns simple sensory inputs into meaningful categories
July 15, 2018 - Deadlier subtype of metastatic prostate cancer found to be common than previously thought
July 15, 2018 - UZH scientists identify enzyme that controls cell division
July 15, 2018 - Unhealthy Food Behaviors May Signal Eating Disorder in Teen
July 15, 2018 - Study raises doubts on a previous theory of Parkinson’s disease
July 15, 2018 - Grant awarded to study whether stem cells can treat urinary incontinence | News Center
July 15, 2018 - Imaging techniques may help assess immune system recovery in HIV patients
July 15, 2018 - Machine-learning may aid in diagnosis and treatment of mental health disorders
July 15, 2018 - ‘Skin Cancer, Take A Hike!’ program promotes sun safety and skin cancer awareness
July 15, 2018 - Blink Health announces lowest prices for generic prescriptions through Blue Eagle Health
July 15, 2018 - New drug strategy can alleviate multiple behavioral, cellular deficiencies in FXS mouse model
July 15, 2018 - Georgia State professor receives federal grant to study virus similar to Ebola virus
July 15, 2018 - Quitting Smoking? Even a Little Exercise Can Help You Stay Slim
July 15, 2018 - DBS treatment may slow the progression of Parkinson’s tremor in early-stage patients
July 15, 2018 - 5 Questions: Luby on virus with potential to cause global pandemic | News Center
July 15, 2018 - Corn loses its cancer-fighting phenolic acids when processed into cornflakes
July 15, 2018 - Study uncovers possible link between iron loading, alcohol intake and mortality
July 15, 2018 - Molecular insights of NagA enzyme could help combat TB
July 15, 2018 - The Facts on Tampons—and How to Use Them Safely
July 15, 2018 - Normalisation of ‘plus-size’ risks hidden danger of obesity, study finds
July 15, 2018 - $2.5 million award to support physician-scientist training | News Center
July 15, 2018 - Aeras announces publication of Phase 2 results of two TB vaccines
July 15, 2018 - Public to set research priorities in field of ethnic inequalities and severe mental illness
July 15, 2018 - Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
July 15, 2018 - U.S. obesity rates rising again
Shorter Preventive TB Tx Effective for HIV+ Patients

Shorter Preventive TB Tx Effective for HIV+ Patients

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • A shorter duration of preventive therapy for tuberculosis (TB) in HIV-positive individuals, a 1-month course of isoniazid/rifapentine, was comparable to the lengthier usual-care regimen for rates of TB and death.
  • Note that serious adverse events occurred in 5.6% of patients in the intervention group and 7.1% of the controls, but the difference was not significant.

BOSTON — A shorter duration of preventive therapy for tuberculosis (TB) in HIV-positive individuals was comparable to the lengthier usual-care regimen for rates of TB and death, a late-breaking phase III randomized trial presented here found.

A 1-month course of isoniazid/rifapentine, an antibiotic regimen for TB prevention, was found to be safe and effective when compared with the usual 9-month course of isoniazid alone in people with HIV infection, reported Richard E. Chaisson, MD, of Johns Hopkins University in Baltimore.

Constance Benson, MD, of the University of California San Diego, who moderated the press conference at the Conference on Retroviruses and Opportunistic Infections (CROI), but was not involved in the research, characterized these findings as having “the potential to immediately change clinical practice.”

In a separate statement released by the National Institutes of Health, Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, agreed, saying that these results “offer people living with HIV who are at risk of developing active [TB] an additional, shorter-duration prevention option that is safe, effective and more convenient.”

At the press conference, Chaisson said that while prevention of TB with isoniazid is effective, “uptake has been appallingly bad.” He added that the longer the course of the therapy is, the more people stop taking it, and described “a sense of futility” among clinicians about this problem.

A shorter, 4-week course of rifapentine and isoniazid had shown promise in animal studies, the authors said, so they hypothesized it would be non-inferior to the usual 9-month standard of care. “The bottom line is,” Chaisson added, “it was.”

Participants were eligible if they were HIV-infected individuals age 13 or older with no evidence of active TB, who had either a positive TB skin or blood test (Interferon Gamma Release Assay, or IGRA) or lived in an area with a high burden of TB (prevalence ≥60/100,000 population). They were stratified by CD4-positive cell count and antiretroviral therapy (ART) use at entry.

After randomization, patients received either 300-mg isoniazid plus 450- to 600-mg rifapentine once daily for 4 weeks or 300-mg isoniazid daily for 9 months. They were then followed for 3 years after the last participant was enrolled. ART with efavirenz or nevirapine was permitted.

Overall, 1,488 patients in the intervention group and 1,498 patients in the control group were included in the analysis. More than half were women, two-thirds were black and median body mass index was 23.5. Median CD4 count was 470 cells/mm³, and half were on ART at entry. Around 20% had a positive TB skin or blood test. The primary endpoint was the incidence rate ratio of active TB, TB death, or death due to an unknown cause, and the non-inferiority margin was 1.25 per 100 person-years.

The intervention group had an incidence of 0.65 per 100 person-years and the control group had an incidence of 0.67 per 100 person-years (IRR difference 0.023, 95% CI -0.30 to 0.35).

Rates of the primary outcome were higher for patients not on ART at entry and those with a positive TB skin or blood test, but no difference between treatments was noted, the authors said. In addition, rates were higher in the intervention group among those with baseline CD4 counts of ≤250 mm3, but the difference was not statistically significant.

Serious adverse events occurred in 5.6% of patients in the intervention group and 7.1% of the controls, but the difference was not significant. The authors noted that safety was “similar” in both arms, with more hematologic toxicity in the intervention group and more liver and neurotoxicity in the control group.

Chaisson said that the study was unlikely to be replicated, but characterized this as a “large enough, clear enough answer that it can be acted upon.” He added that he hoped this therapy would be studied in people without HIV.

The next steps would be incorporating these findings into guidelines. Chaisson said that he shared his results with the World Health Organization and encouraged them to incorporate this into new guidelines, perhaps as an amendment, “as quickly as possible.”

Chaisson disclosed support from Otsuka.

Sanofi supplied study medications for this trial.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-09-03T00:00:00-0400

last updated

Tagged with:

About author

Related Articles